SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

$COCK.X is trending due to the launch of Cocky Wings LLC, a real-world business selling chicken wings, which aims to drive revenue for token buybacks. The community is excited about the potential of a meme coin with real-world utility, with many highlighting the connection to the Cardano chain ($ADA.X).

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential price targets and its role in the Real World Asset (RWA) narrative. The recent partnership with the U.S. Department of Commerce to provide economic data on-chain has generated excitement, with many believing this could signal further adoption by governments and institutions.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as its community rallies around its fair launch and Bitcoin-native nature, contrasting it with other meme coins. Community members are actively discussing its potential to outperform Dogecoin and its strong connection to the Bitcoin network. There's also excitement surrounding potential exchange listings and the involvement of C2 Blockchain.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

ProShares Short Dow30 ($DOG) is trending as traders discuss its potential as a hedge against market downturns and a way to profit from an expected decrease in the Dow Jones. The community highlights its appeal as a Bitcoin-native memecoin with a fair launch and strong community support. Some traders are comparing it to Dogecoin ($DOGE) and touting its potential to "flip" DOGE, while others are considering it for downside protection amid economic uncertainty.

YUPFUN is a Solana-based meme and DeFi project that fuses viral meme culture with real decentralized finance utility. It aims to create a fun, community-driven ecosystem where users can trade, stake, and bridge tokens seamlessly across multiple liquidity pools and decentralized exchanges (DEXs) like BitStorage.finance Raydium, Orca, Meteora, PumpSwap, MintMe.com. YUPFUN isn't just about memes — it's about empowering the community with real ownership through fair launch mechanics, liquidity incentives, and cross-chain accessibility. The project also promotes creative engagement by encouraging users to create and share memes, art, and participate in community-driven events to grow the YUPFUN brand. With no VC backing, no private sales, and no hidden agendas, YUPFUN represents a true decentralized, permissionless movement blending entertainment with real blockchain functionality.

YUPFUN Token

YUPFUN.X is trending as social media buzz highlights the project's unique qualities and potential for virality. Community members are expressing strong bullish sentiment, citing positive chart indicators. The overall tone suggests excitement about YUPFUN's potential impact.

This isn’t just another token. $RISK is a symbol, a call to the fearless, the dream-chasers, the ones who know that greatness only comes to those who are willing to leap.  Born from the legendary phrase “risk it for the biscuit,” $RISK is a tribute to boldness. It’s made for those who refuse to settle, who thrive on high-stakes moments, and who would rather go all in than live with the regret of playing it safe.  In the world of $RISK, there are no participation trophies. You either take the shot or you miss the opportunity.  This token represents a lifestyle, the mindset that: 	•	Playing it safe never made legends. 	•	Caution doesn’t make history. 	•	Only the bold get rewarded.

ItForTheBiscuit

ItForTheBiscuit (RISK.X) is trending amid community excitement surrounding its team and recent technical breakouts. Discussions highlight strong community conviction and potential for further growth, with some focusing on chart patterns suggesting positive momentum. The project's fundamentals and its potential within the broader meme coin landscape are also being actively discussed.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

Fueled by news of a land sale agreement potentially boosting NAV, Gyrodyne is trending as traders discuss its low float and potential for a significant squeeze. Community members are closely watching key breakout levels, anticipating a rapid price increase if momentum continues. The stock's historical volatility and potential for a meme-driven rally are also contributing to the current buzz.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is trending following positive Phase 2 trial data for their uveal melanoma treatment, darovasertib, and crizotinib combination, as well as a successful FDA meeting regarding accelerated approval. The community is discussing the potential for this therapy to transform cancer care and address unmet medical needs, especially given upcoming catalysts and clinical data updates. Analysts are also weighing in with price target increases.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as chatter increases around a potential licensing deal with AstraZeneca and positive trial data, sparking community speculation about an imminent catalyst. The community is actively debating the significance of recent developments and whether they will lead to a substantial rise. Bullish investors are pointing to insider buying and strong analyst ratings, while others remain cautious, awaiting further confirmation.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

Alnylam (ALNY) is trending amid discussions around potential catalysts from pipeline readouts and a recent collaboration with Roche. Community members are analyzing wave structures and identifying potential buying opportunities based on technical analysis. Bullish sentiment is driven by growth expectations for Amvuttra and Alnylam's RNAi platform, though some express valuation concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Summit Therapeutics (SMMT) shares were in the spotlight on Thursday after Guggenheim initiated coverage of the stock with a ‘Buy’ rating and a $40 price target.The price target represents a 70% upside from the stock’s closing price on Wednesday. SMMT stock has had a good run over the past year, nearly doubling in value.Guggenheim said that it liked Summit at $3 when the market was overlooking imminent data comparing progression-free survival with Summit’s Ivonescimab versus Merck's (MRK) blockbuster drug Pembrolizumab in lung cancer. Notably, the analyst said that they still like the stock at $24.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SMMT">SMMT stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, &nbsp;while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:585/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_11_41_23_AM_png_000895180e.webp" alt="SMMT's Sentiment Meter and Message Volume as of 11:41 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="585" height="62"><figcaption>SMMT's Sentiment Meter and Message Volume as of 11:41 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they see sustained growth potential for the stock.<stembedurl>https://stocktwits.com/db59/message/627464707</stembedurl>Guggenheim stated that if Summit's two late-stage clinical trials, HARMONi-3 and HARMONi-7, evaluating Ivonescimab in non-small cell lung cancer (NSCLC) are successful on progression-free survival or overall survival endpoints in 2027-2028, it has high conviction that the stock still has multi-fold upside potential from today's near-$20 billion valuation.While progression-free survival (PFS) is the length of time a patient with a disease, such as cancer, lives with the disease without it getting worse, or dies, overall survival (OS) is the total length of time a patient lives from the point of diagnosis or the start of treatment until death.HARMONi-3 is intended to evaluate Ivonescimab combined with chemotherapy compared to Pembrolizumab combined with chemotherapy in patients with first-line metastatic, squamous and non-squamous NSCLC. HARMONi-7 is intended to evaluate Ivonescimab monotherapy compared to Pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors produce a high amount of the PD-L1 protein.SMMT stock is up 32% this year and approximately 96% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/agios-pharma-stock-slumps-but-company-remains-top-pick-for-analyst/chwdJJlRdYs">Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Summit Therapeutics Gets A $40 Price Target From Guggenheim: Analyst Says It Likes The Stock At $24, Just Like It Did At $3

The price target of $40 represents an upside of 70% from the stock’s closing price on Wednesday.

Equity

Summit Therapeutics drew heavy retail interest on Tuesday after its partner, Akeso, reported that ivonescimab (AK112), a closely watched lung cancer drug, helped patients live longer in a key late-stage trial.Akeso said the final analysis of the Phase III study in patients with EGFR-mutated, advanced non-squamous non-small cell lung cancer who had already failed EGFR-TKI therapy showed ivonescimab extended overall survival, meeting the trial’s main goal with a clear and meaningful benefit.&nbsp;Detailed data will be presented at an upcoming medical conference.The update came alongside Akeso’s first-half earnings and drove its Hong Kong-listed shares up as much as 5.92% on Wednesday. Meanwhile, Summit, which holds U.S. rights to ivonescimab, rose as much as 14% Tuesday on the news.&nbsp;While the drug is already approved in China, Summit is running a similar trial with a broader, global population to pave the way for an approval in the U.S.Ivonescimab has already won two approved indications in China: for EGFR-mutated NSCLC after EGFR-TKI therapy, and as monotherapy for PD-L1-positive advanced NSCLC.&nbsp;The drug has been included in clinical treatment guidelines, and Akeso has launched over 30 trials, including 13 Phase III studies and six head-to-head comparisons with PD-(L)1 therapies.Bernstein analysts led by Rebecca Liang called the survival data “a positive surprise,” noting that whether the drug could extend overall survival “has been the center of debate for AK112 since last year,” Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-27/akeso-s-lung-cancer-drug-hits-key-goal-in-china-study">reported</a>.&nbsp;They added it could be the biggest positive catalyst for Akeso since the company announced ivonescimab had outperformed Merck &amp; Co.’s top-selling cancer drug in a separate trial.On Stocktwits, retail sentiment was ‘extremely bullish’ for Summit Therapeutics amid ‘extremely high’ message volume, while Akeso drew ‘bullish’ sentiment with ‘high’ activity.One user speculated that Summit shares could reach $35 by&nbsp;the end of the week.&nbsp;<stembedurl>https://stocktwits.com/___dog___/message/626653621</stembedurl>Another suggested the stock was still digesting the overall survival news and argued it should already be trading above $30.<stembedurl>https://stocktwits.com/BooEmmy/message/626614344</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 51.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/AKESF">Akeso’s U.S.-listed shares</a> have more than tripled over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside

Analysts at Bernstein called the survival data “a positive surprise,” framing it as Akeso’s biggest catalyst since the drug previously outperformed Merck’s top-selling cancer therapy.

Can Keytruda Sustain Merck's Growth Through the Rest of 2025?

MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.

SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus

Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.

Merck Stock Down 4% Since Q2 Results: How to Play the Stock

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.

Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?

MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth. 

Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits?

ELV's second-quarter earnings may face pressure as rising costs and lower Medicaid memberships offset strong revenue gains.

Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?

MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.

SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca

Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.

AstraZeneca PLC (AZN) and Summit Therapeutics Inc (SMMT) are reportedly discussing a $15 billion partnership to license the latter’s lung-cancer drug.The companies have been holding talks regarding a potential partnership over Summit’s Ivonescimab treatment, Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-03/summit-is-said-in-talks-for-15-billion-partnership-with-astra?srnd=phx-industries-health">reported</a>, citing people familiar with the matter.While the terms of the partnership agreement are still being negotiated, it could include an upfront payment worth several billion dollars and milestone payments, the report said, while noting that the talks could not culminate in a deal as well.Summit has also held talks with other pharmaceutical firms, the report said.Shares of SMMT were trading 5% higher in morning trade following the news, while AZN stock was down by about 2%.Summit, a biopharmaceutical oncology company, said in late May that its global late-stage study evaluating Ivonescimab met the progression-free survival (PFS) primary endpoint but failed to achieve a statistically significant benefit in overall survival.In the late-stage study evaluating Ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherapy in patients with a type of lung cancer, the former demonstrated a statistically significant and clinically meaningful improvement in progression-free survival.Progression-free survival (PFS) essentially measures how long a patient lives with their disease without it getting worse.Ivonescimab in combination with chemotherapy also showed a positive trend in overall survival in the primary analysis, but without achieving a statistically significant benefit. Overall survival reflects the extent to which a treatment can extend a patient’s lifespan.However, there are no current FDA-approved regimens that have demonstrated a statistically significant overall survival benefit in this patient setting, the company said.Summit then said that it intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration seeking approval for Ivonescimab plus chemotherapy based on the results of the trial. However, the firm noted that the FDA had said that a statistically significant overall survival benefit is necessary to support marketing authorization, which will weigh into its consideration of the timeline for filing the application.Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration. It was engineered by Chinese biopharmaceutical company Akeso Inc., and out-licensed to Summit for development and commercialization in regions including the United States and Europe in late 2022.On Stocktwits, retail sentiment around Summit is trending in the ‘bullish’ territory while sentiment around AZN is in the ‘bearish’ territory.SMMT stock is up by about 35% this year, while AZN stock is up by about 7%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/ast-spacemobile-lands-100-million-financing-deal/chFjHRvRcoX">AST SpaceMobile Lands $100M Financing Deal, But Retail Stays Skeptical</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: Report

While the terms of the partnership agreement are still being negotiated, it could include an upfront payment worth several billion dollars and milestone payments, Bloomberg reported, while noting that the talks could not culminate in a deal as well. 

SMMT
Summit Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SMMT News

SMMT Summit Therapeutics Inc